In cervical cancer, TGCA amplifications in CD274 (PD-L1) and PDCD1LG2 (PD-L2) immune targets were found to be associated with this type of cancer [25], and PD-L1 amplification and polysomy have been shown to represent valid prognostic biomarkers in the treatment with anti-PD-L1s [26]. This evidence concerns the gene PDCD1LG2 and cervical cancer.